Phase 2 N=10 A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Subjects Requesting and Requiring an Open Rhinoplasty
Primary: Edema Severity — 1.25; 1.5; 1.25; 1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=131 Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root
Nasal Augmentation
Primary: Mean Difference of Change in Volume (mL) at 6 Months After Baseline Versus Pre-treatment in the Nasal Dorsum/Nasal Root Between Restylane Perlane Treatment Group and…
N/A N=30 Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty
Rhinoplasty
Primary: Live Assessment of Satisfaction With the Grafts — 2; 4 units on a scale
N/A N=29 JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose
Asian Nose Enhancement
Primary: Percentage of Participants With a ≥ 1 Grade Improvement on the Assessment of Aesthetic Improvement Scale (AAIS) as Assessed by the Central Evaluating Physician at Day…
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
N/A N=50 Treatment of Nasal Airway Obstruction Using the Aerin Medical Device
Nasal Obstruction
Primary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
N/A N=39 Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device
Nasal Obstruction
Primary: Change From Baseline NOSE Score — 53.3; 48.1; 53.5 units on a scale — p=<0.0001
N/A N=94 Barrow Nasal Inventory Survey
Pituitary Tumors
Primary: Change in Mean Survey Response From Baseline to 90 Days Post Surgery — 17.3; 13.5 units on a scale — p=0.001
N/A N=20 Treatment Outcome Using Vivaer Stylus to Treat Nasal Airway Obstruction
Nasal Obstruction
Primary: Change in NOSE Score — -44.5 units on a scale
N/A N=50 A Clinical Evaluation of the Sinexus Intranasal Splint Following Functional Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis
Chronic Sinusitis
Primary: Device Success Rate — 14; 76; 10 ethmoid sinuses
N/A N=113 Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study
Nasal Obstruction
Primary: The Primary Efficacy Endpoint is the Percent of Treatment Responders — 101 Participants
Phase 4 N=42 The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
Nasal Obstruction
Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…
Phase 2 N=141 Postoperative Pain Management in Rhinoplasty
Pain, Postoperative
Primary: Pain Intensity Visual Analog Scale (VAS)- 0-100 (0- no Pain and 100- Most Severe Pain) — 44; 41 score on a scale — p=0.156
Phase 4 N=70 Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty
Rhinoplasty · Non-steroidal Ant Inflammatory Drugs · Opioid Use
Primary: Average Pain Score — 2.54; 3.14 score on a scale
N/A N=47 Nasal Septal Flap for Donor Site Reconstruction
Nasal Septum Perforation
Primary: Mean Change in Post-operative Remucosalization at the Donor Site — 47.8; 37.8; 49.7; 43.5 percentage of remucosalization
Phase 4 N=50 Septorhinoplasty Post-operative Pain Control With SPG Nerve Block
Deviated Nasal Septum
Primary: Post Operative Pain Scores — 3.9; 3.8; 2.7; 2.9 pain score on a scale of 0-10
N/A N=32 Comparison of Nasal Steroids After FESS in CRSwNP
Sinusitis · Nasal Polyps
Primary: SNOT-22 Scores — 31.5; 10.29; 15.88 units on a scale
N/A N=60 Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose
Nasolabial Folds
Primary: Treatment Difference in VAS (Perlane Side - Perlane-L Side) With Difference in VAS >= 10 mm — 95 Participants
N/A N=26 The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
Ecchymosis
Primary: Assess Extent of Bruising — .617; .736 a ratio of pixels
Phase 3 N=48 The Nasal Changes Affected by Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy
Conditions in T74.31 or T76.31
Primary: Soft and Hard Tissue Landmarks Movement — 0.95; -0.5; -0.95; -0.32 mm — p=0.098
N/A N=33 InFlux System for Nasal Breathing Improvement
Nasal Airway Obstruction
Primary: Incidence of Unanticipated Serious Adverse Device Effects — 0 events
Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
N/A N=116 RhinAer Procedure for Treatment of Chronic Rhinitis Study
Chronic Rhinitis
Primary: Reflective Total Nasal Symptom Score (rTNSS) Responder Rate — 52; 16 Participants
N/A N=16 Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty
Nasal Obstruction
Primary: Operative Time — 35; 423 seconds
N/A N=164 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults
Nose Enhancement
Primary: Volume Change From Baseline in the Nose Area — -0.005; 2.032 cubic centimeters (cc) — p=<0.0001
N/A N=166 LATERA-OFFICE Study
Nasal Obstruction
Primary: Efficacy: Percent of Treatment Responders — 136 Participants
N/A N=119 Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
Nasal Airway Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale - 3 Month Responder Rate — 88.3; 42.5 percentage of participants
N/A N=100 Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis
Chronic Rhinitis
Primary: Change From Baseline in Symptom Severity — -3.1 score on a scale — p=<0.001
N/A N=30 Multi-Treatment PNN Modulation for Chronic Rhinitis
Chronic Rhinitis
Primary: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE) — 0 Participants
N/A N=30 Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse
Nasal Valve Collapse
Primary: Implant-related Adverse Events — 5 participants